Skip to main content
Figure 2 | Critical Care

Figure 2

From: Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

Figure 2

Adjusted estimated survival curves in subsets stratified according to baseline APACHE II scores. (A) Moderate-risk subset of patients (APACHE II score <24). (B) High-risk subset (APACHE II score = 24 to 29). (C) Very high-risk subset (APACHE II score ≥30). Solid line, patients in the rhTM group; dotted line, patients in the control group. Administration of rhTM was only associated with significantly reduced mortality in patients in the high-risk subset (APACHE II score = 24 to 29; P = 0.025, Cox regression analysis). APACHE, Acute Physiology and Chronic Health Evaluation; rhTM, recombinant human soluble thrombomodulin.

Back to article page

Critical Care

ISSN: 1364-8535